![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Fudan University |
---|---|
Information provided by: | Fudan University |
ClinicalTrials.gov Identifier: | NCT00874406 |
The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.
Condition | Intervention | Phase |
---|---|---|
Colorectal Cancer |
Drug: tac + folfox4 Drug: folfox4 |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer |
Estimated Enrollment: | 100 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
|
Drug: tac + folfox4
tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later: operation within 28 days after operation: folfox4
|
2: Active Comparator
Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
|
Drug: folfox4
folfox4 will be done within 28 days after liver resection
|
We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: jianmin xu, MD, PHD | 008613501984869 | xujmin@yahoo.com.cn |
China | |
Zhongshan Hospital, Fudan University | Recruiting |
shanghai, China, 200032 | |
Contact: jianmin xu, MD, PHD 008613501984869 xujmin@yahoo.com.cn | |
Principal Investigator: jianmin xu, MD, PHD |
Principal Investigator: | jianmin xu, MD, PHD | department of general surgery, zhongshan hospital, fudan university |
Responsible Party: | Zhongshan hospital, Fudan University ( Xujianmin ) |
Study ID Numbers: | 2009-04 |
Study First Received: | April 1, 2009 |
Last Updated: | April 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00874406 History of Changes |
Health Authority: | China: Ministry of Health |
colorectal cancer liver metastasis neoadjuvant chemotherapy |
Oxaliplatin Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Neoplasm Metastasis |
Gastrointestinal Neoplasms Intestinal Diseases Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |
Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Intestinal Neoplasms Neoplasms |
Neoplastic Processes Pathologic Processes Neoplasms by Site Digestive System Diseases Neoplasm Metastasis Gastrointestinal Neoplasms Colorectal Neoplasms |